Formulation and Evaluation of Nanosuspension Delivery System for Simvastatin

Abstract

Poor water solubility and slow dissolution rate are issues polydispersity index. The obtained results showed that for the majority of upcoming and existing biologically active 
 particlesize (nm) and rate of dissolution has been improved compounds. Simvastatin is poorly water-soluble drug and when nanosuspension prepared with the higher its bioavailability is very low from its crystalline form. The concentration of PVPK-30 with the higher concentration of purpose of the present investigation was to increase the 
 PVP K-30 and Poloxamer-188 and lower concentration of solubility and dissolution rate of simvastatin by the SLS. The partical size and zeta potential of optimized preparation of nanosuspension by Emulsification Solvent formulation was found to be 258.3 nm and 23.43. The rate Diffusion Method at laboratory scale. Prepared nanosus- of dissolution of the optimized nanosuspension was pension was evaluated for its particle size and in vitro enhanced (90.02% in 60 min), relative to plain simvastatin dissolution study and characterized by zeta potential, (21% in 60 min), mainly due to the formation of nanosized differential scanning calorimetry (DSC) and X-Ray particles. These results indicate the suitability of 23 factorial diffractometry (XRD), motic digital microscopy, entrapment design for preparation of simvastatin loaded efficiency, total drug content, saturated solubility study and nanosuspension significantly improved in vitro dissolution in vivo study. A 23 factorial design was employed to study rate, and thus possibly enhance fast onset of therapeutic the effect of independent variables, amount of SLS (X1), drug effect. In vivo study shows increase in bioavailability in amount of PVPK-30 (X2) and Poloxamer-188 (X3) and nanosuspension formulation than the plain simvastatin dependent variables are total drug content and drug.

Fabrication, characterization and in vitro evaluation of silibinin nanoparticles: an attempt to enhance its oral bioavailability

“…Particle size reduction due to conversion of the unprocessed drug to the NPs caused a reduction in crystallinity and thus attainment of the amorphous form, which has a lower enthalpy value than the parent unprocessed drug. 11 , 32 , 41 , 42 …”

Fluconazole nanoparticles prepared by antisolvent precipitation technique: Physicochemical, in vitro, ex vivo and in vivo ocular evaluation

“…The formulations F3 (42.4 ± 3.6), F4 (45.5 ± 5.2), and F7 (37.8 ± 5.5) had an increase in their release compared to F0 (32.8 ± 1.1) which might be due to their increased solubility compared to F0 (2.8 ± 0.808, 5.2 ± 1.418, 3.3 ± 0.332, and 1.2 ± 0.215 mmol/mL, respectively). F16 had the highest release of FLZ (63.8 ± 0.0); this might be explained by the SLS surfactant characteristic, which lowers the surface tension, thereby promoting the adequate release of the nanoparticle from the sodium alginate gel formulation ( Shid et al, 2014 ). To find out the release mechanism that suitable depicts the model of drug release, the in vitro release records were tested using the zero order, first order, Higuchi diffusion model, and Korsmeyer-Peppas model.…”

Evaluation of Antitumor Efficacy of Chitosan-Tamarind Gum Polysaccharide Polyelectrolyte Complex Stabilized Nanoparticles of Simvastatin

“…The supernatant was extracted, and the quantity of un-incorporated drug was calculated based on absorption of supernatant solution at 238 nm recorded using a UV spectrophotometer (UV-1800, Shimadzu, Japan). 40,41 Entrapment Efficiency % ð Þ ¼ Total drug À Free drug Total drug x100 (1)…”